Market Snapshot: Diabetic Macular Edema, Another Blockbuster Opportunity For Retinal Drugs?
Having relatively rapidly built a multi-billion dollar market in wet age-related macular degeneration, biotech and pharma companies may be about to repeat the exercise with diabetic macular edema, a complication of diabetes that’s growing in importance as the population ages and the disease spreads.
You may also be interested in...
Clearside Says Uveitis Indication For Xipere Would Keep Company Afloat
Following failure and discontinuation of Phase III studies in retinal vein occlusion, company says it will have enough cash to get through 2020.
Eleven Biotherapeutics Shifts Focus After Trial Failure
Absorbing a 69% stock price crash after the failure of its pivotal trial of EBI-005 in dry-eye disease, Eleven Biotherapeutics explains why it still has faith in other ocular indications and candidates.
Roche’s pRED Team Reviews R&D Wish List As Firm Continues Push To Diversify
In an interview at the J.P. Morgan meeting, Roche R&D and partnering execs John Reed and Sophie Kornowski-Bonnet review progress and aspirations in new therapeutic areas like ophthalmology, antimicrobials and CNS diseases.